The cohort which received the combination therapy with GLP-1 RA and SGLT2i demonstrated a significantly lower risk of HF exacerbations (−9%), overall unplanned emergency department attendance or admissions to hospital (−8%), new-onset atrial arrhythmias (−1%), new-onset AKI (−6%), and pulmonary hypertension (−2%), compared to the SGLT2i-only cohort. This evidence concerns the gene GLP1R and hydrops fetalis.